Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) traded down 7.8% during trading on Friday . The stock traded as low as $12.65 and last traded at $12.76. 26,772 shares traded hands during trading, a decline of 61% from the average session volume of 68,420 shares. The stock had previously closed at $13.84.
Gyre Therapeutics Price Performance
The business's fifty day simple moving average is $13.83 and its two-hundred day simple moving average is $13.00.
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported $0.01 earnings per share for the quarter. The firm had revenue of $25.23 million during the quarter. Gyre Therapeutics had a negative return on equity of 119.54% and a negative net margin of 60.75%. As a group, equities research analysts expect that Gyre Therapeutics, Inc. will post -0.45 EPS for the current fiscal year.
Institutional Investors Weigh In On Gyre Therapeutics
Several large investors have recently bought and sold shares of GYRE. FMR LLC acquired a new stake in Gyre Therapeutics in the 3rd quarter valued at about $47,000. Barclays PLC increased its holdings in shares of Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company's stock valued at $116,000 after purchasing an additional 6,855 shares during the last quarter. Rhumbline Advisers purchased a new position in Gyre Therapeutics during the second quarter worth approximately $123,000. Renaissance Technologies LLC purchased a new stake in Gyre Therapeutics in the 2nd quarter valued at $166,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Gyre Therapeutics in the 2nd quarter worth $218,000. 23.99% of the stock is currently owned by hedge funds and other institutional investors.
About Gyre Therapeutics
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Featured Stories
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
